Innoviva EBIT 2010-2024 | INVA
Innoviva ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Innoviva Annual EBIT
(Millions of US $) |
| 2023 |
$114 |
| 2022 |
$474 |
| 2021 |
$375 |
| 2020 |
$321 |
| 2019 |
$246 |
| 2018 |
$238 |
| 2017 |
$184 |
| 2016 |
$109 |
| 2015 |
$32 |
| 2014 |
$-34 |
| 2013 |
$-29 |
| 2012 |
$-25 |
| 2011 |
$-110 |
| 2010 |
$-78 |
| 2009 |
$-81 |
Innoviva Quarterly EBIT
(Millions of US $) |
| 2024-09-30 |
$43 |
| 2024-06-30 |
$55 |
| 2024-03-31 |
$26 |
| 2023-12-31 |
$38 |
| 2023-09-30 |
$18 |
| 2023-06-30 |
$29 |
| 2023-03-31 |
$30 |
| 2022-12-31 |
$24 |
| 2022-09-30 |
$289 |
| 2022-06-30 |
$83 |
| 2022-03-31 |
$78 |
| 2021-12-31 |
$105 |
| 2021-09-30 |
$95 |
| 2021-06-30 |
$97 |
| 2021-03-31 |
$79 |
| 2020-12-31 |
$85 |
| 2020-09-30 |
$84 |
| 2020-06-30 |
$76 |
| 2020-03-31 |
$76 |
| 2019-12-31 |
$74 |
| 2019-09-30 |
$61 |
| 2019-06-30 |
$60 |
| 2019-03-31 |
$52 |
| 2018-12-31 |
$77 |
| 2018-09-30 |
$58 |
| 2018-06-30 |
$63 |
| 2018-03-31 |
$41 |
| 2017-12-31 |
$66 |
| 2017-09-30 |
$40 |
| 2017-06-30 |
$48 |
| 2017-03-31 |
$29 |
| 2016-12-31 |
$38 |
| 2016-09-30 |
$28 |
| 2016-06-30 |
$26 |
| 2016-03-31 |
$18 |
| 2015-12-31 |
$17 |
| 2015-09-30 |
$8 |
| 2015-06-30 |
$5 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$-10 |
| 2014-06-30 |
$-10 |
| 2014-03-31 |
$-15 |
| 2013-12-31 |
$19 |
| 2013-09-30 |
$-8 |
| 2013-06-30 |
$-7 |
| 2013-03-31 |
$-33 |
| 2012-12-31 |
$-30 |
| 2012-09-30 |
$-33 |
| 2012-06-30 |
$-36 |
| 2012-03-31 |
$86 |
| 2011-12-31 |
$-36 |
| 2011-09-30 |
$-29 |
| 2011-06-30 |
$-24 |
| 2011-03-31 |
$-21 |
| 2010-12-31 |
$-18 |
| 2010-09-30 |
$-20 |
| 2010-06-30 |
$-19 |
| 2010-03-31 |
$-21 |
| 2009-12-31 |
$-21 |
| 2009-09-30 |
$-21 |
| 2009-06-30 |
$-21 |
| 2009-03-31 |
$-18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.199B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
